Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie über aktuelle Versorgungsstandards im wirklichen Leben bei Teilnehmern mit rezidiviertem und/oder refraktärem multiplem Myelom (MoMMent)

2. November 2026 aktualisiert von: Janssen Pharmaceutica N.V., Belgium

Eine prospektive, multinationale Studie über die aktuellen Behandlungsstandards im wirklichen Leben bei Patienten mit rezidiviertem und/oder refraktärem multiplem Myelom

The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Intervention / Behandlung

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

256

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Edegem, Belgien, 2650
        • UZ Antwerpen
      • Genk, Belgien, 3600
        • Ziekenhuis Oost-Limburg
      • Leuven, Belgien, 3000
        • UZ Leuven
      • Mons, Belgien, 7000
        • Chu Helora Hospital De Mons Site Kennedy
      • Sint-Niklaas, Belgien, 9100
        • Vitaz
      • Yvoir, Belgien, 5530
        • Ucl de Mont-Godinne
      • Berin, Deutschland, 12203
        • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
      • Cologne, Deutschland, 50397
        • Universitaetsklinikum Koeln
      • Dresden, Deutschland, 01307
        • Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden
      • Hamburg, Deutschland, 20251
        • Universitätsklinik Hamburg-Eppendorf - Orthopädische Universitätsklinik und Poliklinik
      • Hamm, Deutschland, 59073
        • St. Barbara-Klinik Hamm GmbH
      • Heidelberg, Deutschland, 69120
        • Universitaetsklinikum Heidelberg
      • Karlsruhe, Deutschland
        • Staedtisches Klinikum Karlsruhe gGmbH
      • Leipzig, Deutschland, 4103
        • Universitaetsklinikum Leipzig
      • Leipzig, Deutschland, 04103
        • MVZ Mitte-Onkologische Schwerpunktpraxis
      • Tübingen, Deutschland, 72076
        • Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany
      • Würzburg, Deutschland, 97080
        • Universitatsklinikum Wurzburg
      • Zwickau, Deutschland, 08060
        • Heinrich-Braun-Klinikum gGmbH
      • Lille, Frankreich, 59037
        • CHRU de Lille Hopital Claude Huriez
      • Montpellier, Frankreich, 34295
        • CHU de Montpellier Hopital Saint Eloi
      • Nantes, Frankreich, 44093
        • CHU de Nantes hotel Dieu
      • Pierre-Bénite, Frankreich, 69495
        • Centre hospitalier Lyon-Sud
      • Toulouse, Frankreich, 31059
        • Pôle IUC Oncopole CHU
      • Alexandroupoli, Griechenland, 68100
        • University Hospital of Alexandroupolis
      • Athens, Griechenland, 115 26
        • Henry Dunant Hospital Center
      • Athens, Griechenland, 115 28
        • Alexandra Hospital
      • Athens, Griechenland, 115 27
        • Laiko General Hospital Of Athens 1
      • Athens, Griechenland, 115 27
        • Laiko General Hospital of Athens 2
      • Piraeus, Griechenland, 18537
        • Metaxa Cancer Center Hospital Of Piraeus
      • Rio, Griechenland, 265 04
        • General University Hospital of Patras
      • Thessaloniki, Griechenland, 546 39
        • Anticancer Hospital of Thessaloniki Theageneio
      • Thessaloniki, Griechenland, 54636
        • Ahepa University General Hospital of Thessaloniki
      • Bari, Italien, 70124
        • U.O. Ematologia Istituto Tumori Giovanni Paolo II
      • Bari, Italien, 70124
        • Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II
      • Bologna, Italien, 40138
        • Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi
      • Catania, Italien, 95128
        • Policlinico di Catania
      • Civitanova Marche, Italien, 62012
        • Ospedale Civile di Civitanova Marche
      • Genova, Italien, 16132
        • Ospedale Policlinico San Martino IRCCS
      • Genova, Italien, 16132
        • IRCCS Azienda Ospedaliera San Martino - IST
      • Lecce, Italien, 73100
        • Ospedale Vito Fazzi
      • Meldola, Italien, 47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
      • Padova, Italien, 35128
        • Universita degli Studi di Padova Azienda Ospedaliera di Pa
      • Palermo, Italien, 90146
        • Ospedale Villa Sofia-Cervello
      • Pavia, Italien, 27100
        • Fondazione IRCCS Policlinico San Matteo
      • Pescara, Italien, 65124
        • Presidio Ospedaliero Pescara
      • Reggio Calabria, Italien, 89124
        • Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria
      • Roma, Italien, 00168
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Roma, Italien, 128
        • Campus Bio Medico di Roma
      • Roma, Italien, 00161
        • Università di Roma La Sapienza
      • San Giovanni Rotondo, Italien, 71013
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • San Giovanni Rotondo, Italien, 71013
        • Casa Sollievo Della Sofferenza IRCCS
      • Tricase, Italien, 73039
        • Ospedale Cardinale G. Panico
      • Vicenza, Italien, 36100
        • Azienda Ulss 8 Berica- Ospedale Di Vicenza
      • Amsterdam, Niederlande, 1081 HV
        • VU Medisch Centrum
      • Groningen, Niederlande, 9713 GZ
        • UMCG
      • Chaves, Portugal, 5400 482
        • Ulstmad - Hosp. Chaves
      • Coimbra, Portugal, 3004 561
        • Uls Coimbra - Hosp. Univ. Coimbra
      • Porto, Portugal, 4200 319
        • Uls Sao Joao - Hosp. Sao Joao
      • Bucharest, Rumänien, 022328
        • Fundeni Clinical Institute
      • Bucharest, Rumänien
        • Spitalul Clinic Coltea, Clinica Hematologie
      • Cluj-Napoca, Rumänien, 400015
        • Institutul Oncologic Prof Dr. Ion Chiricuta Cluj Napoca 1
      • Chur, Schweiz, 7000
        • Kantonsspital Graubunden
      • Winterthur, Schweiz, 8400
        • Kantonsspital Winterthur, Medizinische Onkologie
      • Zurich, Schweiz, 8091
        • Universitatsspital Zurich
      • Zurich, Schweiz, 8032
        • Hirslanden Klinik Hirslanden
      • Barcelona, Spanien, 08908
        • Inst. Cat. Doncologia-H Duran I Reynals
      • Gijón, Spanien, 33394
        • Hosp. de Cabuenes
      • Granada, Spanien, 18014
        • Hosp. Univ. Virgen de Las Nieves
      • Jerez de la Frontera, Spanien, 11407
        • Hosp. de Jerez de La Frontera
      • León, Spanien, 24008
        • Hosp. de Leon
      • Madrid, Spanien, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spanien, 28034
        • Hosp. Univ. Ramon Y Cajal
      • Palma, Spanien, 7120
        • Hosp. Univ. Son Espases
      • Pamplona, Spanien, 31008
        • Clinica Univ. de Navarra
      • Salamanca, Spanien, 37007
        • Hosp Clinico Univ de Salamanca
      • Santander, Spanien, 39008
        • Hosp. Univ. Marques de Valdecilla
      • Santiago de Compostela, Spanien, 15706
        • Hosp. Clinico Univ. de Santiago
      • Valencia, Spanien, 46010
        • Hosp. Clinico Univ. de Valencia
      • Valencia, Spanien, 46017
        • Hosp. Univ. Dr. Peset
      • Valladolid, Spanien, 47003
        • Hosp. Clinico Univ. de Valladolid
      • Zaragoza, Spanien, 50009
        • Hosp. Univ. Miguel Servet
      • Bristol, Vereinigtes Königreich, BS10 5NB
        • Southmead Hospital
      • London, Vereinigtes Königreich, NW1 2PG
        • University College Hospital
      • London, Vereinigtes Königreich, SE5 9RS
        • Kings College Hospital
      • London, Vereinigtes Königreich, SW17 OQT
        • St Georges Hospital
      • Maidstone, Vereinigtes Königreich, ME16 9QQ
        • Maidstone Hospital
      • Nottingham, Vereinigtes Königreich, NG5 1PB
        • Nottingham University Hospitals NHS Trust
      • Surrey, Vereinigtes Königreich, SM2 5PT
        • The Royal Marsden NHS Trust Sutton
      • Leoben, Österreich, 8700
        • LKH Leoben
      • Vienna, Österreich, 1060
        • Krankenhaus der barmherzigen Schwestern

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population consists of participants with previously treated multiple myeloma, having received standard of care (SOC) antimyeloma treatments during local clinical practices.

Beschreibung

Inclusion Criteria:

  • For Period 1 and 2: Have a documented diagnosis of multiple myeloma according to International myeloma working group (IMWG) diagnostic criteria. For Period 3: Start of talquetamab for the treatment of a documented diagnosis of relapsed and/or refractory multiple myeloma (RRMM) according to IMWG diagnostic criteria and the approved indication. The decision to start talquetamab must be made independently of the decision to participate in the study, with the start of treatment occurring up to 28 days following the start of screening or having occurred up to 21 days before the informed consent form (ICF) date
  • For Period 1 and 2: Have an Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1. For Period 3: Have ECOG performance status of 0,1 or 2
  • For Period 1,2 and 3: Must not be pregnant or must not plan to become pregnant within the study period
  • For Period 1,2 and 3: Participants must sign an ICF indicating that he or she understands the purpose and observational nature of the study and is willing to participate. Consent is to be obtained prior to the initiation of any study-related data collection
  • For Period 1 and 2: Received at least 3 prior lines of therapy (induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen). Undergone at least 1 complete cycle of treatment for each line of therapy, unless progressive disease (PD) was the best response to the line of therapy
  • For Period 1 and 2: Must have documented evidence of progressive disease based on participating physician's determination of response by the IMWG response criteria on or after the last regimen. Participants with documented evidence of progressive disease within the previous 6 months and who are refractory or non-responsive to their most recent line of treatment afterwards are also eligible
  • For Period 1 and 2: Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M-protein level 200 mg/24 hours; or Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Period 1: Received as part of previous therapy a PI, an IMiD, and an anti-CD38 antibody (prior exposure can be from different monotherapy or combination regimens)
  • Period 2: Received as part of previous therapy a PI, an IMiD, an anti-CD38 antibody, and BCMA-targeted therapy (prior exposure can be from different monotherapy or combination regimens)
  • For period 3: At least one of the following prior to the start of talquetamab: a. Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) or urine M-protein level >= 200 milligram (mg) /24 hours; or b. serum immunoglobulin free light chain >= 10 milligrams per deciliter (mg/dL) and abnormal ratio of involved and uninvolved free light chains or c. presence of bone lesions or plasmacytomas (>=1 lesion has 2 diameters >= 1 centimeter [cm])

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Participants with Relapsed/Refractory Multiple Myeloma

Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant.

There is no interventional treatment component for participants with RRMM in this study.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Response Rate (ORR)
Zeitfenster: Up to 52 months

Overall Response Rate is defined as the percentage of participants who achieve a partial response (PR) or better response according to the International Myeloma Working Group (IMWG) response criteria, as assessed by Response Review Committee (RRC).

Up to 52 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Very Good Partial Response (VGPR) Rate
Zeitfenster: Up to 52 months

VGPR rate is defined as the percentage of participants who achieve a VGPR or better response according to IMWG response criteria.

Up to 52 months
Complete Response (CR) Rate
Zeitfenster: Up to 52 months

CR rate is defined as the percentage of participants who achieve a CR or better response according to IMWG response criteria.

Up to 52 months
Stringent Complete Response (sCR) Rate
Zeitfenster: Up to 52 months

sCR rate is defined as the percentage of participants who achieve a sCR according to IMWG response criteria.

Up to 52 months
Minimal Residual Disease (MRD) Negative Rate
Zeitfenster: Up to 52 months

MRD negative rate is defined as the percentage of participants with negative MRD status according to IMWG response criteria.

Up to 52 months
Clinical Benefit Rate (CBR)
Zeitfenster: Up to 52 months

CBR is defined as the percentage of participants with clinical benefit. CBR=ORR (sCR + CR + VGPR + PR) + minimal response (MR).

Up to 52 months
Duration of Response (DOR)
Zeitfenster: Up to 52 months

DOR is defined as time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease as defined in the IMWG criteria.

Up to 52 months
Time to Response (TTR)
Zeitfenster: Up to 52 months

TTR is defined as the time between the date of Day 1 of Cycle 1 and the first clinical response evaluation that the participant has met all criteria for PR or better response.

Up to 52 months
Time to Best Response
Zeitfenster: Up to 52 months

Time to best response is defined as the time between the date of Day 1 of Cycle 1 and best objective response.

Up to 52 months
Time to Next Treatment (TTNT)
Zeitfenster: Up to 52 months

TTNT is defined as the time from diagnosis to the start of the next-line treatment.

Up to 52 months
Progression-free Survival (PFS)
Zeitfenster: Up to 52 months

PFS is defined as the time from the date of Day 1 of Cycle 1 to the date of first documented disease progression (as defined in the IMWG response criteria) or death due to any cause, whichever occurs first.

Up to 52 months
Time to Progression on the Next Line of Subsequent Antimyeloma Therapy or Death, Whichever Occurs First (PFS2)
Zeitfenster: Up to 52 months

PFS2 is defined as the time from the date of Day 1 of Cycle 1 to progression on the next line of subsequent antimyeloma therapy or death, whichever occurs first.

Up to 52 months
Overall Survival (OS)
Zeitfenster: Up to 52 months

OS is the duration from the date of Day 1 of Cycle 1 to the date of the participant's death or study completion, whichever occurs first.

Up to 52 months
Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
Zeitfenster: Baseline up to 52 months

The EORTC-QLQ-C30 Version 3 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

Baseline up to 52 months
Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Zeitfenster: Baseline up to 52 months

The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

Baseline up to 52 months
Period 1 and 2: Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EORTC QLQ-IL39
Zeitfenster: Baseline up to 52 months

EORTC QLQ-IL39 (four single items from the EORTC QLQMY20) will be performed to assess emotional health status (feel restless or agitated, thinking about your illness, worried about dying, worried about health in the future) on scale of 1 (not at all) to 4 (very much).

Baseline up to 52 months
Number of Participants with Adverse Events (AEs)
Zeitfenster: Up to 52 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 52 months
Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Zeitfenster: Up to 52 months

Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening consequences; Grade 5: Death related to adverse event.

Up to 52 months
Period 3: Number of Participants Reporting Oral Toxicities Using Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Zeitfenster: Up to 52 months

PRO-CTCAE consist of 1-8 questions of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. The following items were selected for inclusion for patients with multiple myeloma: nausea, vomiting, diarrhea, shortness of breath, rash, dizziness, headache, taste changes, and fatigue/tiredness/lack of energy.

Up to 52 months
Period 3: Number of Participants Reporting Oral Toxicity Symptoms Using the Epstein Taste Survey (ETS)
Zeitfenster: Up to 52 months

The Epstein Taste Survey consists of 17 items from the full 71 item PRO instrument, specific to taste changes. Developed for use in patients with head and neck cancer.

Up to 52 months
Period 3: Percentage of Participants with Overall Response to Subsequent Therapies
Zeitfenster: Up to 52 months

Overall Response Rate is defined as the percentage of participants who achieve a partial response (PR) or better response according to the International Myeloma Working Group (IMWG) response criteria, as assessed by Response Review Committee (RRC). Overall response for subsequent therapies, including BCMA-targeted therapies after treatment with talquetamab will be reported.

Up to 52 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Janssen Pharmaceutica N.V., Belgium Clinical Trial, Janssen Pharmaceutica N.V., Belgium

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

18. November 2021

Primärer Abschluss (Geschätzt)

30. April 2028

Studienabschluss (Geschätzt)

30. Oktober 2028

Studienanmeldedaten

Zuerst eingereicht

15. Dezember 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. Dezember 2021

Zuerst gepostet (Tatsächlich)

16. Dezember 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren